3,5-diamino-N-carbamimidoyl-6-(6-methoxybenzofuran-2-yl)pyrazine-2-carboxamide

ID: ALA4547122

PubChem CID: 155552505

Max Phase: Preclinical

Molecular Formula: C15H15N7O3

Molecular Weight: 341.33

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  COc1ccc2cc(-c3nc(C(=O)NC(=N)N)c(N)nc3N)oc2c1

Standard InChI:  InChI=1S/C15H15N7O3/c1-24-7-3-2-6-4-9(25-8(6)5-7)10-12(16)21-13(17)11(20-10)14(23)22-15(18)19/h2-5H,1H3,(H4,16,17,21)(H4,18,19,22,23)

Standard InChI Key:  SRWPULZHZGLGIJ-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 25 27  0  0  0  0  0  0  0  0999 V2000
   19.3635  -13.2731    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.3624  -14.0927    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.0704  -14.5016    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   20.7801  -14.0922    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.7773  -13.2695    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.0686  -12.8643    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   21.4884  -14.4997    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   18.6544  -14.5007    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   21.4834  -12.8583    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.1927  -13.2642    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   21.4804  -12.0411    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   22.8988  -12.8529    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.6081  -13.2589    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   22.8958  -12.0358    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   18.6578  -12.8649    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.5728  -12.0525    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   17.9123  -13.1944    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.3672  -12.5881    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.7763  -11.8849    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.3719  -11.1811    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.5586  -11.1793    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.1513  -11.8872    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.5580  -12.5881    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.1503  -10.4715    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   16.5591   -9.7639    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  1  1  0
  4  7  1  0
  2  8  1  0
  5  9  1  0
  9 10  1  0
  9 11  2  0
 10 12  1  0
 12 13  1  0
 12 14  2  0
  1 15  1  0
 15 16  1  0
 16 19  1  0
 18 17  1  0
 17 15  2  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 18  1  0
 21 24  1  0
 24 25  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4547122

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 341.33

Molecular Weight (Monoisotopic): 341.1236

AlogP: 0.69

#Rotatable Bonds: 3

Polar Surface Area: 179.16

Molecular Species: NEUTRAL

HBA: 8

HBD: 5

#RO5 Violations: ┄

HBA (Lipinski): 10

HBD (Lipinski): 8

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 11.77

CX Basic pKa: 6.11

CX LogP: 0.63

CX LogD: 0.61

Aromatic Rings: 3

Heavy Atoms: 25

QED Weighted: 0.34

Np Likeness Score: 0.01

References

1. Buckley BJ, Majed H, Aboelela A, Minaei E, Jiang L, Fildes K, Cheung CY, Johnson D, Bachovchin D, Cook GM, Huang M, Ranson M, Kelso MJ..  (2019)  6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.,  29  (24): [PMID:31679971] [10.1016/j.bmcl.2019.126753]

Source

Source(1):

• Scientific Literature